Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04139317
Title	Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1 >= 50%
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	lung non-small cell carcinoma
Therapies	Capmatinib + Pembrolizumab Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	NLD \| ITA \| GRC \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS